PubMed Health⌕ Search

Biomedical subjects

Z Uddin

Publications and source records attributed to Z Uddin.

6 recordsLinked to original sources
PubMed2001

Normal proliferative responses of peripheral blood mononuclear cells to streptococcal preparation OK-432 in patients with pustulosis palmaris et plantaris constitute a distinct feature from the reduced responses observed in those with psoriasis vulgaris, pustular psoriasis, and acrodermatitis continua of Hallopeau.

It was previously reported that peripheral blood mononuclear cells (PBMC) from the patients with psoriasis vulgaris (PV) showed a reduced proliferative response in vitro to the stimulation of a lyophilized preparation of penicillin-treated low virulence Su-strain of Streptococcus pyogenes group 3, OK-432. In this study, at first it was examined whether OK-432 acts as a superantigen. By analyzing the usage of Vbeta T-cell receptor (TCR) of proliferating T cells stimulated with OK-432, it was found that OK-432 stimulated preferentially Vbeta2 TCR-bearing T cells. Next, to find differences in in vitro responses of PBMC among various types of sterile pustular dermatoses such as pustulosis palmaris et plantaris (PPP), acrodermatitis continua of Hallopeau (AC), and generalized pustular psoriasis (GPP), the proliferative responses of PBMC obtained from these patients under the stimulation of OK-432 were compared. When the PBMC was stimulated with interleukin (IL)-2, no significant difference was found in their proliferative responses among those obtained from the patients with these sterile pustular dermatoses, PV or healthy controls. However, like those from PV patients, PBMC from AC and GPP patients showed significantly smaller responses to OK-432 than those from the healthy controls. In contrast, the proliferative responses of PBMC from the patients with PPP to OK-432 was comparable to those from healthy controls. These results, in addition to its unique clinical and histopathological characteristics, suggest that PPP has a different pathogenetic background from that underlying PV, AC, or GPP.

Acrodermatitis↗
PubMed2000

Troponin I sensitivity and specificity for the diagnosis of acute myocardial infarction.

This article describes the sensitivity and specificity of troponin I when compared to creatine kinase-MB (CK-MB) and electrocardiography (ECG) for diagnosing acute myocardial infarction (AMI). Two different lower levels for defining positive results with troponin I were evaluated. A retrospective study of 153 patients who presented to the emergency department of a community hospital supplied the pool of patients for this study. Patients included in this study were those for whom a CK-MB was ordered. The majority of these patients were evaluated for chest pain or symptoms suggesting an acute cardiac event. Of the 153 patients studied, CK-MB results were positive in 91 (59%) patients; ECG revealed AMI in 72 (47%) patients. There were 103 (67%) patients who had either positive CK-MB or ECG results. Ninety (59%) patients had a troponin I level greater than 2.0 ng/mL, and 18 (12%) patients had a troponin I level between 0.6 and 2.0 ng/mL. Seven patients whose troponin I level was between 0.6 and 2.0 ng/mL had negative CK-MB and ECG results. Therefore, 11 patients with troponin I between 0.6 and 2.0 ng/mL had AMI. Five patients with positive troponin I results (> 2.0 ng/mL) had negative CK-MB and ECG results. When a troponin I level greater than 0.6 ng/mL was used as a positive value, compared to CK-MB and ECG using either time zero or time 6 hours, the sensitivity was 94% and specificity was 81%. When troponin I greater than 2.0 ng/mL was used to define a positive test, the sensitivity was 85% and specificity was 91% when compared to CK-MB and ECG.

Adult↗
PubMed1999

Creating a hospital-community infrastructure: challenges and benefits.

With rising public expectations and demands for increased accountability, hospitals will be even more challenged by their local communities to implement strategies such as those developed at SMH to enable community participation that assists the hospital in serving its local population into the future. In response to unique health needs of its local community, SMH created an Inner City Health (ICH) Program in the early 1990s to provide comprehensive inpatient, ambulatory, and community outreach services. To build on its philosophy to reduce barriers to health for disadvantaged populations, the ICH Research Program, the only one of its kind in Canada, was also established. This paper will describe and explore the formalised infrastructure between SMH and the community; its evolution, as well as SMH's involvement with its community in context of the hospital's relationships with its Board of Directors, the Toronto teaching hospital system, media and advocacy groups. The role of ICH research in influencing evidence-based clinical practice, innovations in health science education and government policy will also be discussed as part of the SMH's hospital-community infrastructure.

Canada↗
PubMed1997

Public-private management partnerships in the Canadian environment: options for medical imaging.

Health services restructuring demands that hospitals consider innovative ways of providing patient care, including services within the clinical support departments such as medical imaging, diagnostic laboratories and pharmacy. This Brief Report describes the result of work carried out a St. Michael's Hospital to explore options for public-private management partnerships within the Department of Medical Imaging. Various partnership models and opportunities for cost containment, revenue generation and strategic positioning are discussed.

Ancillary Services, Hospital↗
PubMed1997

Public-private partnerships in the Canadian environment: options for hospital pharmacies.

This brief report explores the direction being pursued by hospitals interested in outsourcing non-core activities within the pharmacy department. Private sector logistics companies are looking to position themselves in the drug product supply chain to facilitate seamless transfers of drug products, ordering information and payments between drug manufacturers and hospitals. Opportunities for implementing consolidated purchasing, unit dosing, just-in-time inventory and electronic commerce systems are discussed.

Commerce↗